StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Non-GAAP Diluted Earnings per Share by Year

Non-GAAP Diluted Earnings per Share ($) ($)

Merck Non-GAAP Diluted Earnings per Share: $8.98 in FY2025, up 17.4% from a year earlier.

Latest, FY2025
8.98
Period ended Dec 31, 2025
Change on a year earlier
+17.4%
7.65 in FY2024
History
5 years
Since FY2020
Sources
4
Documents cited below

Where the FY2025 figure comes from

“|| Earnings per Common Share Assuming Dilution | $ | 7.28 | (0.99 | ) | (0.83 | ) | 0.10 | 0.02 | (1.70 | ) | $ | 8.98”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Supplemental Table 2a (GAAP to Non-GAAP Reconciliation).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Diluted Earnings per Share ($) ($)Year on yearSource
FY2025Dec 31, 20258.98+17.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 20247.65+406.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 20231.51-79.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 20227.48–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2020Dec 31, 20204.53–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗

Breakdown

What makes up non-GAAP Diluted Earnings per Share

Cite this data

StockData. (2026). Merck Non-GAAP Diluted Earnings per Share ($), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/nongaap-eps

See every metric in the Merck KPI table. Data updated Oct 26, 2026.